Date de publication

26 décembre 2019

Auteur(s)

Kuo PH., Sun HY. et autres

Description

OBJECTIVE:

To evaluate the evolution of weight and lipid profiles before and after switch to coformulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) among virally suppressed HIV-positive patients.

METHODS:

Between March and July 2018, patients switching to E/C/F/TAF were included. Weight, lipid profiles (triglyceride [TG], total cholesterol [TC], high-density lipoprotein cholesterol [HDL-C], and low-density lipoprotein cholesterol [LDL-C]), and glycated hemoglobin (HbA1C) 48 weeks before and after switch were analyzed using generalized estimating equation to identify the associated factors.

RESULTS:

Of 693 patients included, weight gain was noted after switch at Weeks 12 (mean +0.63 kg), 24 (+1.25), 36 (+1.58), and 48 (+1.75) (all p < 0.0001). Weight change after switch was significantly greater than that observed within the preceding 48-week period before switch (+1.75 kg vs +0.54, p < 0.0001) and was correlated with switch to E/C/F/TAF (coefficient 0.29), later clinic visit (0.15), baseline weight (0.99), diabetes mellitus (coefficient -0.96), and age (-0.02) (all p < 0.01). At Week 48, significant increases were observed for TG (mean +62.93 mg/dl), TC (+22.30), LDL-C (+9.70), HDL-C (+3.65) (all p < 0.01) and HbA1C (+0.08%) (p < 0.05), but not TC/HDL-C ratio (+0.12, p = 0.38).

CONCLUSION:

Virally suppressed HIV-positive patients gained a moderate amount of weight and had significant increases of lipid levels after switch to E/C/F/TAF.